Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART002g1 in Heterozygous Familial Hypercholesterolemia
NCT07353398Phase 1Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Mar 2026
- Primary completion
- Jul 2027
- Modality
- CRISPR-Cas9, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label trial of ART002g1 in heterozygous familial hypercholesterolemia (HeFH) (3 arms), sponsored by Shanghai General Hospital. Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) at 48 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
ART002g1
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT07353398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07353398.